Monte Rosa Therapeutics presents preclinical data at ACR on MRT-6160

Monte Rosa Therapeutics (GLUE) announced the company will present preclinical data on the potential of MRT-6160, a rationally designed molecular glue degrader that selectively degrades VAV1, to treat multiple autoimmune and inflammatory diseases, at ACR Convergence 2025, held October 24-29 in Chicago, IL. Summary of key findings: MRT-6160, a first-in-class VAV1-directed MGD, potently degraded VAV1 and attenuated T and B cell effector functions in both healthy and rheumatic disease patient donor-derived peripheral blood mononuclear cells. In vitro data demonstrated that MRT-6160 decreased TfH cell-mediated B cell activation, differentiation, and immunoglobulin secretion. In the spontaneous autoimmune disease MRL-Faslpr mouse model, oral administration of MRT-6160 resulted in attenuated proteinuria, lymphadenopathy, skin lesion formation, autoantibody production, organomegaly, and kidney glomerular and interstitial nephritis. MRT-6160 was equivalent or superior to prednisone or anti-CD40L monoclonal antibody treatments across multiple metrics of disease pathology.